Cytokinetics Stock Performance
| CYTK Stock | USD 37.23 1.66 4.27% |
The firm shows a Beta (market volatility) of 0.61, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cytokinetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cytokinetics is expected to be smaller as well. Cytokinetics right now shows a risk of 3.24%. Please confirm Cytokinetics treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Cytokinetics will be following its price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Cytokinetics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Cytokinetics is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return (4.27) | Five Day Return (2.54) | Year To Date Return (23.91) | Ten Year Return 464.09 | All Time Return (61.46) |
Last Split Factor 1:6 | Last Split Date 2013-06-25 |
1 | Disposition of 5000 shares by Robert Blum of Cytokinetics at 40.96 subject to Rule 16b-3 | 04/29/2025 |
2 | Acquisition by Wysenski Nancy of 10880 shares of Cytokinetics at 30.0 subject to Rule 16b-3 | 05/14/2025 |
3 | Acquisition by Harrington Robert Arthur of 7333 shares of Cytokinetics subject to Rule 16b-3 | 05/23/2025 |
4 | Disposition of 5000 shares by Robert Blum of Cytokinetics at 31.22 subject to Rule 16b-3 | 06/02/2025 |
5 | Cytokinetics Down 1.9 percent Since Last Earnings Report Can It Rebound | 06/05/2025 |
6 | Disposition of 5000 shares by Robert Blum of Cytokinetics at 33.8 subject to Rule 16b-3 | 06/16/2025 |
7 | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 06/17/2025 |
8 | Insider Sell Alert Fady Malik Sells 2,000 Shares of Cytokinetics Inc | 06/18/2025 |
9 | Cytokinetics, Incorporated Given Consensus Recommendation of Moderate Buy by Brokerages | 07/01/2025 |
10 | Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of ... | 07/10/2025 |
11 | Disposition of 5000 shares by Robert Blum of Cytokinetics at 38.15 subject to Rule 16b-3 | 07/14/2025 |
12 | Robert I. Blum Sells 5,000 Shares of Cytokinetics, Incorporated Stock | 07/17/2025 |
13 | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 CYTK Stock News | 07/18/2025 |
| Begin Period Cash Flow | 113.4 M | |
| Total Cashflows From Investing Activities | -553.1 M |
Cytokinetics | Build AI portfolio with Cytokinetics Stock |
Cytokinetics Relative Risk vs. Return Landscape
If you would invest 3,781 in Cytokinetics on April 22, 2025 and sell it today you would lose (58.00) from holding Cytokinetics or give up 1.53% of portfolio value over 90 days. Cytokinetics is currently generating 0.0278% in daily expected returns and assumes 3.2365% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Cytokinetics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytokinetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytokinetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cytokinetics, and traders can use it to determine the average amount a Cytokinetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0086
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYTK |
Estimated Market Risk
| 3.24 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cytokinetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cytokinetics by adding Cytokinetics to a well-diversified portfolio.
Cytokinetics Fundamentals Growth
Cytokinetics Stock prices reflect investors' perceptions of the future prospects and financial health of Cytokinetics, and Cytokinetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytokinetics Stock performance.
| Return On Equity | -5.72 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (98.56) % | ||||
| Current Valuation | 4.3 B | ||||
| Shares Outstanding | 119.43 M | ||||
| Price To Earning | (37.76) X | ||||
| Price To Book | 60.31 X | ||||
| Price To Sales | 231.36 X | ||||
| Revenue | 18.47 M | ||||
| Gross Profit | (338.46 M) | ||||
| EBITDA | (493.48 M) | ||||
| Net Income | (589.53 M) | ||||
| Cash And Equivalents | 586.03 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 788.68 M | ||||
| Debt To Equity | 2.93 % | ||||
| Current Ratio | 9.01 X | ||||
| Book Value Per Share | (2.23) X | ||||
| Cash Flow From Operations | (395.89 M) | ||||
| Earnings Per Share | (5.29) X | ||||
| Market Capitalization | 4.45 B | ||||
| Total Asset | 1.4 B | ||||
| Retained Earnings | (2.7 B) | ||||
| Working Capital | 928.27 M | ||||
| Current Asset | 113.11 M | ||||
| Current Liabilities | 31.65 M | ||||
About Cytokinetics Performance
By examining Cytokinetics' fundamental ratios, stakeholders can obtain critical insights into Cytokinetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cytokinetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (0.26) | (0.27) | |
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | 4.35 | 4.57 |
Things to note about Cytokinetics performance evaluation
Checking the ongoing alerts about Cytokinetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytokinetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytokinetics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 18.47 M. Net Loss for the year was (589.53 M) with loss before overhead, payroll, taxes, and interest of (338.46 M). | |
| Cytokinetics currently holds about 586.03 M in cash with (395.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22. | |
| Cytokinetics has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 CYTK Stock News |
- Analyzing Cytokinetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytokinetics' stock is overvalued or undervalued compared to its peers.
- Examining Cytokinetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytokinetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytokinetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytokinetics' stock. These opinions can provide insight into Cytokinetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.29) | Revenue Per Share | Quarterly Revenue Growth 0.891 | Return On Assets | Return On Equity |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.